Enzyme inhibitors and enzyme substrates

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.

Potent, selective, competitive CysLT 1 antagonist.

Potent, selective, competitive CysLT 1 antagonist.

Potent, selective, competitive CysLT 1 antagonist.

Potent, selective, competitive CysLT 1 antagonist.

Potent, selective, competitive CysLT 1 antagonist.

Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.An HMGCR inhibitor which blocks cholesterol synthesis.